Genomics Market - By Type, By Technology, By Application, By End Use - Global Forecast, 2025 - 2034

Genomics Market Size

The global genomics market was valued at USD 39 billion in 2024. The market is expected to grow from USD 44.7 billion in 2025 to USD 162 billion in 2034, at a CAGR of 15.4% during the forecast period, according to the latest report published by Global Market Insights Inc. The global genomics field is accelerating rapidly, fueled by the rising incidence of genetic and chronic diseases and a growing demand for precision diagnostics.

Every year, around 7.9 million births globally, approximately 6% of all births are estimated to have a defect of genetic or partially genetic origin. In India alone, more than 495,000 infants are born annually with congenital malformations, around 390,000 with G6PD deficiency, 21,400 with Down syndrome, 9,000 with beta-thalassemia, and 5,200 with sickle cell disease as per National Institutes of Health (NIH). Currently more than 10,000 genetic disorders are classified as rare, affecting hundreds of millions of people. These facts indicate an important need for flexible enhancements in the genomics field to ensure timely and more accurate diagnostic and disease management.
 

Genomics is the study of an organism’s complete DNA, including all genes, enabling insights into disease mechanisms, genetic mutations, and personalized treatment approaches. The rapidly developing market continues to benefit from advancements in artificial intelligence and big data analytics, in addition to other innovations in DNA sequencing, gene editing, and bioinformatics. Use of genomics in personalizing medicine has shifted the focus of the industry around diagnostics, drug discovery, agriculture, forensics, and reproductive health. Major industry players include Illumina, Thermo Fisher Scientific, BGI Genomics, Agilent Technologies, and Roche. These companies are innovators in genomics and are transforming diagnostics, research, and therapeutics.
 

Between 2021 and 2023, the market grew from USD 26 billion to USD 34 billion, bolstered by clinical adoption and government-backed initiatives. Projects such as the Genomics England and the U.S. Precision Medicine Initiative have laid the foundation for global genomics efforts. Twenty years ago, the price was in the millions and today, entire genomes can be sequenced for just a few hundred dollars which enhanced affordability and market reach.
 

Further, there is increasing use of genomic tools in fields such as oncology, rare disease screening, pharmacogenomics, and companion diagnostics. These tools promote more affordable healthcare by directing therapy selection, minimizing adverse drug reactions, and decreasing failures in drug development. Industry leaders invest in developing new tools by broadening their platform offerings, integrating AI-powered analytics, and establishing partnerships with pharmaceutical and biotechnology companies.
 

The deepening use of genomics in healthcare systems, biopharma, and institutions is driven by advancing regulatory frameworks and evolving reimbursement pathways. The genomics market continues to transform diagnostics, therapeutics, and biological discovery, facilitating the movement toward more personalized and predictive medicine.
 

Genomics Market Trends

• The growth driver in the genomics industry is the rapid developments in next generation sequencing (NGS) technologies along with declining price of gene sequencing. For instance, the cost of sequencing an entire human genome has decreased from around USD 1 million in the year 2007 to USD 600 in 2024. This resulted in facilitating more genomic research. One of the industry leaders in genomic technologies, Illumina, is anticipated to further lower the price with the NovaSeq X series, expected to cost around USD 200 per genome, with faster and higher throughput sequencing.
   
• The rising incidence of genetic disorders is also driving the demand for genomic services. The National Institutes of Health (NIH) reports that between 2000 and 2022, a total of 7,481 patients were referred to for genetic testing, and of these, 3,294 were diagnosed with a rare genetic disorder. In this 65% were male and 35% female, which underscores the increasing clinical demand for rapid and precise genetic diagnosis.
   
• This growing demand, coupled with better cost efficiency, is driving the adoption of genomics in clinical and research practice. Genomic testing is being used increasingly for early detection of diseases, personalized treatment, and other preventive measures in healthcare.
   
• Regulatory frameworks are also evolving to support this integration. Agencies such as the U.S. Food and Drug Administration and the European Medicines Agency are creating policies regarding genomic technologies in healthcare that incorporate guidelines on genomic markers, companion diagnostics, and safe data-sharing frameworks.
   
• Additionally, the use of artificial intelligence and machine learning in the analysis of genomic data is a significant trend. This accelerates the pace of innovation and precision medicine by enabling the rapid analysis of large-scale datasets, and the identification of genetic variants associated with diseases. This also predicts responses to treatments and targets for drug discovery.
   
• Direct-to-consumer genetic testing is another factor transforming public engagement with genetic health. As of early 2024, over 40 million people had taken at-home genetic tests offered by companies such as 23andMe and AncestryDNA. This resulted in enhancing awareness of personal genetics, ancestry, and health predispositions.
   
• Genomics is also being applied in forensics, agriculture and environmental science. Genomics in agriculture is contributing to global food security and sustainable farming practices by enabling the development of high-yield, disease-resistant crops.
   

Genomics Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on type, the genomics market is divided into products and services. The product segment is further bifurcated into instruments, consumables and reagents. The products segment accounted for 67.1% of the market in 2024. The segment is expected to exceed USD 105.7 billion by 2034, growing at a CAGR of 15.1% during the forecast period. The services segment is further divided into NGS-based services, core genomics services, biomarker translation services, computational services, and other services.
 

• The products segment of the market mainly comprises instruments and consumables. These are essential for conducting genomic research and diagnosis.
   
• Generating high-throughput genomic data requires NGS platforms, PCR machines, and microarrays. These technologies have evolved rapidly, offering greater speed, accuracy, and scalability. This supports their growing use in clinical and research settings.
   
• Consumables such as reagents, sequencing kits, and sample prep materials are very important in the market as they are repeatedly used in the lab workflow.
   
• As the demand for genomic testing increases in areas such as cancer, and rare diseases the need for consumables continues to rise. Moreover, the increase in implemented personalized medicine and genomic projects reasons for the growing demand in this market segment.
   

Based on technology, the genomics market is segmented into PCR (polymerase chain reaction), sequencing, microarray, nucleic acid extraction and purification, and other technologies. The sequencing segment dominated the market in 2024 with a revenue of USD 14.8 billion.
 

• The sequencing technology segment is a core driver of growth in the market, fueled by advancements in accuracy, speed, and cost efficiency.
   
• This segment is dominated by NGS technology, which allows high-throughput sequencing of DNA and RNA at an incredibly high resolution and scale.
   
• NGS technologies have enabled rapid advances in genomic research and the diagnosis of clinical conditions through the sequencing of entire genomes, exomes, and transcriptomes in a single assay. The NovaSeq platform from Illumina and the Ion Torrent from Thermo Fisher are among the sequencing technologies utilized in research laboratories, hospitals, and biopharmaceutical companies.
   
• Further, long-read sequencing, a feature of the third-generation sequencing technologies, is one of the most notable recent developments in the field. These technologies enable the detection of complex structural variants and enhance problematic parts of the genome assembly process.
   
• In addition, use of these technologies in genomic research for the study of cancers and the surveillance of infectious diseases, as well as the diagnostics of rare diseases, is expanding rapidly.
   

Based on application, the genomics market is segmented into diagnostics, drug discovery and development, precision medicine, agriculture and animal research, and other applications. The diagnostics segment dominated the market in 2024 with a revenue of USD 13.8 billion.
 

• The diagnostics segment holds a significant share driven by the growing need for accurate, early detection and personalized treatment of diseases.
   
• Genomic technologies are increasingly being integrated into clinical diagnostics for a wide range of conditions, including cancer, rare genetic disorders, infectious diseases, and prenatal screening.
   
• NGS technologies facilitate the diagnosis of genetic abnormalities and enable precise targeted treatment, especially in cancer, where tumor profiling assists in choosing optimal treatment.
   
• In rare disease diagnostics, genomics helps identify previously undetectable mutations, shortening the diagnostic journey for patients. Non-invasive prenatal testing (NIPT), based on cell-free fetal DNA analysis, is also gaining widespread adoption due to its safety and reliability.
   
• Lastly, the segment is also fueled by the growing availability of diagnostic genetic tests and the increasing awareness of the clinicians and patients.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, genomics market is classified into hospitals and clinics, research centers and academic and government institutes, pharmaceutical and biotechnology companies, and other end users. The pharmaceutical and biotechnology companies segment dominated the market in 2024 and is expected to reach USD 59.3 billion by 2034.
 

• The pharmaceutical and biotechnology companies segment is important in the innovation and growth of the market. This is because these firms use genomics in technologies in drug discovery and development and personalized medicines.
   
• By utilizing genomic data, they can identify novel drug targets, understand disease mechanisms at a molecular level, and develop targeted therapies tailored to specific genetic profiles. This approach increases the success rates of clinical trials and reduces time-to-market for new treatments.
   
• Many biotechnology companies that focus on gene editing, gene therapy, and precision oncology depend on advanced sequencing and genomic analysis.
   
• In addition, pharmaceutical companies are increasing collaboration with genomics companies to streamline genomic data into the drug development process to improve the drug’s effectiveness and safety.
   
• The increasing need for precision medicine and the growing availability to genomic data will continue to drive growth of this segment, enabling sector-leading innovations in the industry. 

Looking for region specific data?

Download Free PDF

North America Genomics Market
 

The North America market dominated the market with a market share of 42.6% in 2024.
 

• North America remains the market leader owing to its cutting-edge research infrastructure, strong government investment, and elevated uptake of genomics in healthcare and research.
   
• Moreover, the region’s market is supported by investments in precision medicine, active clinical trial frameworks, and partnerships in biotechnology.
   
• The demand for personalized therapies, early disease detection, and non-invasive diagnostics increases market growth. As the region is home to leading innovators within the sequencing, diagnostics, and bioinformatics industries, innovation and accessibility is enhanced.
   
• North America’s dominant market position has been further strengthened by national genomics initiatives, including population-based genomics, and supportive policies in the region.
   

The U.S. genomics market was valued at USD 10 billion and USD 11.5 billion in 2021 and 2022, respectively. The market size reached USD 15.1 billion in 2024, growing from USD 13.2 billion in 2023.
 

• Extensive investments in research and innovative technologies, as well as supportive government actions, including NIH's All of Us Research Program, contribute to making the U.S. the largest and most advanced market in the world.
   
• The expanding market is also the result of high demand for personalized medicine, cancer genomics, and diagnostics for rare diseases. This growth is aided by the presence of large industry players, notable academic institutions, and positive reimbursement coverage.
   
• Continuous innovation in sequencing, diagnostics, and gene editing technologies positions the U.S. at the forefront of global genomics development.
  
   

Europe Genomics Market
 

Europe market accounted for USD 11.1 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Europe is a significant player in the market, driven by strong research capabilities, supportive regulatory frameworks, and growing investments in precision medicine.
   
• The region encompasses some of the top research and biotech companies in the world and active participants in clinical and genomic research. Healthcare improvement initiatives such as the 1+ Million Genomes Project facilitate cross-border collaboration and the exchange of data to improve healthcare results.
   
• The increased market demand is due to the need for earlier disease detection, personalized treatment, and non-invasive prenatal diagnostics. These factors are driving market expansion.
   
• Moreover, public funding and government-backed genomics programs have stimulated the innovation of genomic technologies and broadened their availability to the region.
   

Germany dominates the European genomics market, showcasing strong growth potential.
 

• Germany has one of the strongest healthcare systems in Europe and one of the most sophisticated research and development frameworks. This positions the country as one of the best performing markets in Europe.
   
• The country has a high adoption rate of genomic technologies in areas such as oncology, rare disease diagnostics, and pharmacogenomics. Government initiatives such as the GenomDE project aim to integrate genomic medicine into routine healthcare.
  
   

Asia Pacific Genomics Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 15.9% during the analysis timeframe.
 

• As a result of the increased awareness of healthcare, government investments in the healthcare systems, and the increased adoption of precision medicine, the region is experiencing rapid growth in the market.
   
• Countries such as China, Japan, India, and South Korea, are investing a lot in infrastructure and genomic research. The rising occurrence of chronic and genetic diseases drives the demand for genomic testing and sequencing technologies.
   
• National genome initiatives and public-private partnerships in the region increase the growth rate of research in the region. The total population of the region, in combination with improving healthcare access, further enhances the market’s long-term growth potential.
   

China genomics market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• China is becoming a key player in the global market, backed by government support, and government programs such as the China Precision Medicine Initiative.
   
• The country also focuses on the development of sequencing infrastructure, population genomics, and gene therapy. Companies such as BGI genomics are leading genomic innovation across diagnostics and research in China.
   
• With rising demand for personalized medicine and early disease detection, along with favorable regulatory support, China’s market is poised for significant and sustained growth.
  
   

Latin American Genomics Market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil is one of the leading markets in Latin America, driven by growing investment in healthcare infrastructure, increasing prevalence of chronic and genetic diseases, and expanding research initiatives.
   
• The country has launched national efforts such as the Brazilian Initiative on Precision Medicine (BIPMed), promoting genomic data collection and integration into healthcare.
   
• Academic institutions and public research centers are collaborating with international partners to advance genomic studies. The demand for personalized medicine, cancer genomics, and rare disease diagnostics is rising.
  
   

Middle East and Africa Genomics Market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia is rapidly advancing its market as part of its Vision 2030 strategy to modernize healthcare and promote biotechnology innovation. The country has launched major initiatives such as Saudi Human Genome Program, aimed at mapping genetic data to better understand inherited diseases prevalent in the population.
   
• The combination of government investment and collaboration with foreign genomics companies is streamlining the integration of research with clinical practices. These efforts target rare genetic disorders, and personalized medicine.
   
• With improving infrastructure, skilled workforce development, and regulatory support, Saudi Arabia is positioning itself as a regional leader in genomic science and healthcare innovation.
   

Genomics Market Share

The genomics industry presents a dynamic and moderately consolidated competitive landscape, shaped by the presence of global biotech leaders, diagnostics firms, and emerging genomics-focused startups. Leading companies such as Illumina, Thermo Fisher Scientific, Agilent Technologies, BGI Genomics, and F. Hoffmann-La Roche collectively account for approximately 75% of the market share. Their dominance is driven by continuous innovation in sequencing platforms, expansion of consumables portfolios, and strategic investments in precision medicine and clinical diagnostics.
 

To strengthen their positions, these companies are pursuing multi-faceted strategies including mergers and acquisitions, collaborations with academic and healthcare institutions, and expansion into AI-driven genomic analytics. Their focus remains on improving sequencing speed, reducing costs, and expanding applications in oncology, rare diseases, and reproductive health.
 

Meanwhile, players such as Oxford Nanopore and Pacific Biosciences are fueling innovation through portable sequencers, single-cell genomics, and long-read sequencing technologies. These firms are particularly active in Asia-Pacific, Latin America, and the Middle East, where demand for localized genomics solutions, rising healthcare investments, and government-backed genomic initiatives are accelerating adoption.
 

The market continues to evolve amid growing regulatory clarity, increasing integration of bioinformatics, and a global push toward personalized, data-driven care. Companies are rapidly expanding their product offerings to support real-time diagnostics, population-scale genome programs, and preventive healthcare models, ensuring sustained innovation and global market growth.
 

Genomics Market Companies

Prominent players operating in the genomics industry are as mentioned below:
 

• Agilent Technologies
• BGI Genomics
• Bio-Rad Laboratories
• Color Genomics
• Danaher
• Eppendorf
• Eurofins Scientific
• F. Hoffmann-La Roche
• Illumina
• Myriad Genetics
• NVIDIA
• Oxford Nanopore Technologies
• Pacific Biosciences of California
• QIAGEN
• Quest Diagnostics
• Thermo Fisher Scientific

• Illumina

Illumina is a global player in NGS technologies, known for its high-throughput and cost-efficient platforms such as NovaSeq X. Its sequencing systems are the backbone of large-scale genomic initiatives, including the 100,000 Genomes Project in the UK, enabling population-level precision medicine and advanced genetic research.
 

• Thermo Fisher Scientific

Thermo Fisher Scientific offers one of the most comprehensive genomics portfolios, including NGS platforms, qPCR, genotyping, and CRISPR technologies. Its Ion Torrent sequencing systems are widely used in clinical oncology diagnostics and infectious disease genomics, helping laboratories worldwide achieve faster, scalable, and clinically actionable genomic insights.
 

• BGI Genomics

BGI Genomics is known for its affordable, large-scale sequencing services, making genomics accessible in emerging markets. It played a pivotal role during the COVID-19 pandemic by rapidly sequencing viral genomes and establishing high-throughput testing labs across Asia, supporting public health surveillance and diagnostics on a national scale.
 

Genomics Industry News

• In January 2025, NVIDIA announced new partnerships with leading genomics firms to accelerate drug discovery, genomic research, and AI-driven diagnostics. By combining accelerated computing with biological data, NVIDIA aims to reshape the healthcare and life sciences landscape through agentic and generative AI platforms.
   
• In January 2025, Oxford Nanopore Technologies unveiled PromethION 2 Plus, a compact long-read sequencer enabling rapid, high-throughput genomic and epigenomic analysis, supporting advances in cancer research and infectious disease monitoring.
   
• In February 2025, BGI Genomics partnered with the Ministry of Health in Indonesia to establish a national genomics center focused on infectious disease surveillance and hereditary disorder screening. The facility will use BGI’s low-cost sequencing technologies to expand access to genomic healthcare in Southeast Asia.
   
• In March 2025, Agilent Technologies announced the global launch of its SureSelect XT HS3 Target Enrichment System, designed to enhance the sensitivity and efficiency of genomic sequencing for clinical research. This system reduces workflow time and improves mutation detection in cancer genomics and inherited disease research.
   

The genomics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Billion from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Products       
  • Instruments
  • Consumables and reagents 
• Services       
  • NGS-based services
  • Core genomics services
  • Biomarker translation services
  • Computational services
  • Other services

Market, By Technology

• PCR (polymerase chain reaction)
• Sequencing
• Microarray
• Nucleic acid extraction and purification
• Other technologies

Market, By Application

• Diagnostics
• Drug discovery and development
• Precision medicine
• Agriculture and animal research
• Other applications

Market, By End Use

• Hospitals and clinics
• Research centers and academic and government institutes
• Pharmaceutical and biotechnology companies
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE